VERA · Vera Therapeutics, Inc. · Documents

$29.04 -1.44 (-4.72%) At close · Nov 12 Play latest call Q3 2026 earnings call transcript

Russell 2000 member Rebalance outlook locked

Market Cap

$2.10B

72.30M

Volume · Nov 12 913.89K Avg daily vol (3M) 2.05M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $299.62M 10-K filed Feb 26, 2026 Quarterly report FY2026 Q3 Revenue $10.28M 10-Q filed Nov 5, 2026 Latest results Financial results 8-K filed Nov 5, 2026 Earnings call Q3 2026 earnings call Held Nov 5, 2026

2026

Nov 10

Investor event

Guggenheim 3rd Annual Healthcare Innovation Conference AI summary on its way

Nov 5

Earnings call

Trutacna generated $10.3 million in first partial quarter

Vera Therapeutics reported $10.3 million in Trutacna revenue and approximately 700 patient start forms. It submitted an SBLA seeking full FDA approval, anticipated in mid-2027, supported by a 76% reduction in kidney disease progression risk through 104 weeks.

5 source passages

Good day, and welcome to the Vera Therapeutics Business Update and Financial Results webcast for the quarter ended September 30, 2026. Net product revenue from sales of Schutachna was $10.3 million for the third quarter of 2026, our first partial quarter of commercial sales. Since the accelerated approval of Trutacna on July 7th, we have received approximately 700 patient start forms to date. These results form the basis of the recently submitted SBLA seeking full approval of Trutacna in adults with primary IgA nephropathy, which is anticipated in mid-2027. Trutacna held the rate of kidney function decline to a physiologic level and reduced the risk of kidney disease progression by 76% compared with placebo through 104 weeks. Open the document at this passage

Nov 5

Quarterly report 10-Q FY2026 Q3, ended Sep 30

TRUTAKNA wins FDA approval and launches product sales

Vera Therapeutics’ TRUTAKNA received FDA accelerated approval on July 7, 2026, for adults with primary IgAN at risk for progression; it generated $10.3 million in product revenue through September 30, 2026, while requesting full approval on November 3, 2026.

Revenue $10.28M Net loss $93.71M Diluted EPS -$1.30

Read from the MD&A section

3 source passages

On July 7, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to TRUTAKNA to reduce proteinuria in adults with primary IgAN at risk for disease progression. For the three and nine months ended September 30, 2026, we recorded net product revenue of $10.3 million from sales of TRUTAKNA. On November 3, 2026, we submitted a supplemental Biologics License Application to the FDA requesting potential full FDA approval in mid-2027. Open the document at this passage

Nov 5

Current report 8-K

Financial results AI summary on its way

Oct 22

Investor event

Virtual Investor Event: ASN Kidney Week 2026

Vera Therapeutics reported a 76% reduction in composite kidney progression through week 104 and an annualized eGFR difference of 5 mL per minute per year for atachycept. An FDA submission supporting potential full approval is planned for 2027.

Sep 15

Investor event

Morgan Stanley 24th Annual Global Healthcare Conference AI summary on its way

Sep 15

Current report 8-K

Regulation FD disclosure, Other events AI summary on its way

Aug 10

Current report 8-K

Financial results AI summary on its way

Aug 10

Quarterly report 10-Q FY2026 Q2, ended Jun 30

Quarterly report for FY2026 Q2 AI summary on its way